FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Lifesci Capital cut their FY2024 earnings per share estimates for TScan Therapeutics in a research note issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($1.08) per share for the year, down from their prior estimate of ($1.07). The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics' FY2025 earnings at ($1.08) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $0.54 million for the quarter, compared to analysts' expectations of $1.55 million.

A number of other equities analysts also recently issued reports on the company. Wedbush restated an "outperform" rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Needham & Company LLC reissued a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Friday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

TScan Therapeutics stock traded down $0.41 during midday trading on Friday, reaching $4.41. 244,070 shares of the company traded hands, compared to its average volume of 246,912. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 7.77. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69. The firm has a market capitalization of $233.62 million, a price-to-earnings ratio of -4.14 and a beta of 0.79. The business has a 50 day moving average of $5.33 and a two-hundred day moving average of $6.51.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $70,000. The Manufacturers Life Insurance Company purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $90,000. SG Americas Securities LLC purchased a new position in shares of TScan Therapeutics during the third quarter worth $78,000. XTX Topco Ltd purchased a new stake in TScan Therapeutics during the third quarter worth about $112,000. Finally, Cornercap Investment Counsel Inc. purchased a new stake in TScan Therapeutics during the 2nd quarter worth approximately $134,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Barbara Klencke acquired 5,000 shares of the business's stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the director now directly owns 35,000 shares in the company, valued at $199,150. The trade was a 16.67 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the transaction, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. This represents a 97.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 15,000 shares of company stock worth $82,550. Company insiders own 2.76% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.